<DOC>
	<DOCNO>NCT01134224</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate blood glucose-lowering effect NN5401 ( insulin degludec/insulin aspart ( IDegAsp ) ) subject type 2 diabetes .</brief_summary>
	<brief_title>A Trial Investigating Effect NN5401 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes mellitus ( diagnose clinically ) least 12 month Body mass index equal 35.0 kg/m^2 Subject donate blood plasma past month 500 mL within 3 month prior screen Smoker ( define subject smoke 5 cigarette equivalent per day ) Not able willing refrain smoking use nicotine gum transdermal nicotine patch inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>